547 filings
8-K
MBRX
Moleculin Biotech Inc
18 Apr 24
Regulation FD Disclosure
8:30am
8-K
MBRX
Moleculin Biotech Inc
10 Apr 24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
8:30am
8-K
MBRX
Moleculin Biotech Inc
8 Apr 24
Other Events
5:14pm
8-K
MBRX
Moleculin Biotech Inc
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
9:05am
8-K
MBRX
Moleculin Biotech Inc
25 Mar 24
Regulation FD Disclosure
3:03pm
8-K
ai75s
25 Mar 24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
7:30am
8-K
06vy8no2
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
8-K
mco2gr kt737
20 Mar 24
Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study
7:30am
8-K
mzfd0ne
19 Mar 24
Moleculin Announces Reverse Stock Split
4:31pm
8-K
ocqkahu5aof i0wjrv
29 Feb 24
Regulation FD Disclosure
8:30am
8-K
2jrc5 mfvjc
22 Feb 24
Regulation FD Disclosure
9:30am
424B3
gmmhksp0
16 Feb 24
Prospectus supplement
5:19pm
8-K
01apah
15 Feb 24
Regulation FD Disclosure
9:15am
8-K
dwrvzi39
14 Feb 24
Regulation FD Disclosure
4:36pm
8-K
zkukl
14 Feb 24
Submission of Matters to a Vote of Security Holders
4:33pm
SC 13G
s7ob5tuhlthia 71rbq
14 Feb 24
Moleculin Biotech / ARMISTICE CAPITAL ownership change
3:43pm
EFFECT
6nrt9vttt 2koavq
13 Feb 24
Notice of effectiveness
12:15am
CORRESP
mkkvc
9 Feb 24
Correspondence with SEC
12:00am
UPLOAD
5h8 1xp47ef873
9 Feb 24
Letter from SEC
12:00am